U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
INDIA :
+91-848-285-0837
Press Release: Acellular Dermal Matrices Market to Surpass US$ 15,648.1 Million by 2028
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Acellular dermal matrix (ADM) is a biologically derived product, which is devoid of cells. Acellular dermal matrices were initially used in the resurfacing of burn injuries, abdominal wall repair, tympanic membrane replacement, dural repairs, and gingival grafting. Now ADMs are mostly used in breast surgery and plastic surgery. Also, acellular dermal matrices has a wide application in the management of acute wounds such as burns, traumatic wounds, cancer, and infections, they are also used in the management of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcer, and others and they are also used in the most of the reconstruction procedures such as abdominal wall procedures, which include hernia repair, breast procedures include breast augmentation, orthopedic procedures, and others.
The global acellular dermal matrices market is estimated to be valued at US$ 7,014.0 million in 2021 and is expected to exhibit a CAGR of 12.1% over the forecast period (2021-2028).
Figure 1. Global Acellular Dermal Matrices Market Value (US$ Mn), and Y-o-Y Growth (%), 2018-2028
Increasing number of product launches by key playe rs are expected to drive the market growth over the forecast period.
The key players operating in the global acellular dermal matrices market are focusing on launches and approvals of technologically advanced acellular dermal matrices in the market, which is expected to drive the market growth over the forecast period. For instance, in April 2021, MedSkin Solutions Dr. Suwelack AG, a Germany-based specialized biotech company, launched two new MatriDerm products, MatriDerm Flex Dermal Matrix and MatriDerm Fenestrated Dermal Matrix. The two new products are introduced as an extension of MatriDerm’s product portfolio that offers more flexibility to surgeons for the treatment of complex wounds when it comes to one- and two-stage surgical procedures, which utilizes a split-thickness skin graft.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 7,014.0 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 12.1% | 2028 Value Projection: | US$ 15,648.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Acellular Dermal Matrices Market Share (%), by Application, 2021
Global Acellular Dermal Matrices market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Therefore, the governments and government agencies globally are taking various initiatives to combat the spread of COVID-19.
For instance, the Australian Society of Plastic Surgeons (ASPS), the Australian government organization, and BreastSurgANZ announced various guidelines and regulations for reconstruction procedures. These guidelines included surgeons to take informed consent from patients for performing reconstructive surgery during COVID-19 pandemic, inform about the potential consequences of the surgery done during COVID-19 to the patient and others, to delay the reconstruction procedures if not urgent, to delay immediate autologous flap reconstruction for breast reconstruction. While the regulations stated that the reconstructive surgeons should address only the cancer-related surgeries during COVID-19.
Global Acellular Dermal Matrices market: Restraint
Complications and side effects associated with acellular dermal matrices in breast and plastic surgery is expected to restraint growth of the global acellular dermal matrices market over the forecast period. According to the article published in Plastic and Reconstructive Surgery Journal in February 2019, in the U.S., the rate of plastic surgeries are high as compared to other countries. Moreover, the rate of side-effects and complications associated with plastic surgery such as skin necrosis are caused in 8-15% of the patients undergoing plastic surgery.
Key Players
Major players operating in the global acellular dermal matrices market include Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.
Acellular dermal matrices are generated by decellularization process, which leads to the removal of the cells and preserving of the extracellular matrix. The extracellular matrix ones implanted in the required area, serves as the scaffold for the donor cells. The donor cells help in the revascularization, which in turn generates a new tissue.
Market Dynamics:
The increasing prevalence of breast cancer among the women population is expected to increase the rates of masectomy, which in turn is expected to drive growth of the acellular dermal matrices market growth over the forecast period. For instance, in 2019, according to the World Health Organization (WHO), in India, breast cancer accounts for around 2.09 million cases and 627,000 deaths. It is the most common type of cancer in India and accounts for around 14% of all the cancers in women. It has been estimated that, in India, the incidence rate increases in early thirties and are at its peak at the ages 50-64 years.
Increasing availability of the acellular dermal matrices products in different countries is expected to increase the customer base, which in turn will drive the global acellular dermal matrices market growth over the forecast period. For instance, in 2016, Acelity L.P. Inc., a wound care and regenerative medicine company launched ALLODERM SELECT DUO regenerative tissue matrix in the U.S. The launch will increase the availability of the tissue matrix for the U.S. population undergoing bilateral breast reconstruction.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
*Browse 35 market data tables and 31 figures on "Acellular Dermal Matrices Market” - Global forecast to 2028
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Sales Office (U.S.) : Coherent Market Insights Pvt Ltd, 1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Asia Pacific Intelligence Center (India) : Coherent Market Insights Pvt Ltd, 203, 2nd Floor,
Bremen Business Center, Aundh, Pune,
Maharashtra 411007, India.
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
US :
INDIA :
UK :
JAPAN :
Contact Us
